Navigation Links
VirtualScopics Announces Receipt of Notice from Nasdaq
Date:8/31/2012

ROCHESTER, N.Y., Aug. 31, 2012 /PRNewswire/ -- VirtualScopics, Inc., (NASDAQ: VSCP), a leading provider of image-based solutions to the pharmaceutical, biotechnology and medical device industries, announced today that on August 29, 2012 it received a notice from the NASDAQ Stock Market indicating that the Company's minimum bid price has fallen below $1.00 for 30 consecutive business days.  NASDAQ Marketplace Rule 5550(a)(2)requires a $1.00 minimum bid price for continued listing of an issuer's common stock. 

In accordance with section 5810(c)(3)(A) of the NASDAQ Marketplace Rules, the Company has until February 25, 2013 to regain compliance. The Company can regain compliance with the minimum bid price rule if the bid price of its common stock closes at $1.00 or higher for a minimum of 10 consecutive business days during the 180-day period, although the NASDAQ Stock Market may, in its discretion, require the Company to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days before determining that it has demonstrated the ability to maintain long-term compliance.

Additionally, if compliance with this Rule cannot be demonstrated by February 25, 2013, NASDAQ will determine whether the Company meets the NASDAQ Capital Market initial listing criteria except for the bid price requirement. If the Company meets the initial listing criteria, NASDAQ will notify the Company that it has been granted an additional 180 calendar day compliance period. If the Company is not eligible for an additional compliance period, NASDAQ will notify the Company that its common stock will be delisted. At that time, the Company may appeal this determination to delist its securities to a Listing Qualification Panel.

The Company is actively pursuing a number of initiatives to bring the Company into compliance with the minimum share price requirement.

About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development.  VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images.  In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster.  For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the Company's ability to regain compliance with Nasdaq listing standards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.CONTACTS:Investor Relations:Company Contact:Tim RyanMolly HendersonThe Shoreham Group

Chief Business and Financial Officer, Sr. Vice President80 Eighth Ave, Ste 1107

500 Linden OaksNew York, NY 10011

Rochester, New York 14625+1 212 242 7777 Direct

+1 585 249.6231tryan@shorehamgroupllc.com

'/>"/>

SOURCE VirtualScopics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Schedules Second Quarter 2012 Earnings Announcement
2. VirtualScopics Reports 2nd Quarter 2012 Results
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
10. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
11. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Kingdom and  BOSTON , March 28, 2017 ... Linguamatics today announced a partnership with premium ... agreement allows pharmaceutical companies to extract key insights ... text mining technology. The Linguamatics ... the top 20 global pharmaceutical companies. The Linguamatics-Dow ...
(Date:3/28/2017)... Md. , March 28, 2017  CASI ... to innovative therapeutics addressing cancer and other unmet ... the American Association for Cancer Research annual meeting.  ... 3 is entitled "Evaluation of ENMD-2076 in ... and the second poster to be presented on ...
(Date:3/28/2017)... England , March 28, 2017 ... collaborative research with Cambridge ... Therapeutics Consortium   The Milner Therapeutics Institute today ... Consortium. Elysium Health has committed significant investment for collaborative projects ... the next four years. This is the first major research ...
Breaking Medicine Technology:
(Date:3/28/2017)... Mateo, CA (PRWEB) , ... ... ... Society (RSS), a non-profit medical society dedicated to advancing the science and ... leveraging data from its RSSearch Patient Registry, a multi-institutional, observational registry established ...
(Date:3/28/2017)... ... ... Alert Sentry Group LLC., a leader in the Personal Emergency Response System industry, introduced ... Plus. These iSAFE products are the most affordable and most advanced medical alert systems ... direct GPS Location and two-way calling with the push of a button on a ...
(Date:3/28/2017)... ... ... WHO: , Dr. Paul Thomas; Dr. Brian Hooker; Dr. Judy Mikovits; Dr. Jennifer ... speak to the press on behalf of over 200 doctors, scientists, and scientific organizations ... , WHERE: , Zenger Room, National Press Club, 529 14th Street NW, 13th ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business Management ... begun to serve as its new executive director. Mr. Still was selected through a ... , “Bob, as he is known to our members, has been a part ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... physicians, Paul Yost, will begin serving as new board chair for Orange County ... Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which ...
Breaking Medicine News(10 mins):